A sharp integral inequality for closed spacelike submanifolds immersed in the de Sitter space

Archiv der Mathematik - In this paper, we establish a sharp integral inequality for n-dimensional closed spacelike submanifolds with constant scalar curvature immersed with parallel normalized mean...     

Application of TiO2-nanotubes/PbO2 as an anode for the electrochemical elimination of Acid Red 1 dye

Journal of Solid State Electrochemistry - In this study, galvanostatic electrolysis, through the use of the platinum supported on Ti (Ti/Pt) and Ti/TiO2-nanotubes/PbO2 anodes, was conducted in an...     

Thermal stability of the PBAT biofilms with cellulose nanostructures/essential oils for active packaging

The primary objective of this study is to evaluate the thermal stability of the active films with the cellulose nanostructure (CNS, 5?mass%) treated with encapsulated essential oils (EOs), eugenol and linalool. CNS untreated and treated were incorporated in the poly(butylene adipate-co-terephthalate) (PBAT) polymer matrix prepared by casting. In this study, all samples were characterized by FTIR, DRX, TG, DSC and SEM, elucidating the contribution of each component in the final films. CNS untreated and treated with EOs were characterized by Fourier transform infrared spectroscopy and thermogravimetric analysis (TGA), confirming the interaction between these components. The active biofilms were analyzed by TGA and DSC analyses (differential scanning calorimetry), confirming that their thermal stability was maintained similar to the neat PBAT film, without loss of properties. The CI (crystallinity index, %) of the polymeric films was calculated from heat fusion (ΔH) values, indicating that the incorporation of the nanostructures into the PBAT matrix increases the crystallinity of the biofilms, from 11.5 (neat PBAT) to 13.8% (PBAT/CNS-E), acting as a nucleating agent in the polymeric matrix. The presence of the EOs did not decrease the CNS stability, as well of the biocomposite films. Moreover, the thermal analysis confirmed that the EO was well involved by the CNS, before and after the incorporation in the PBAT polymer, as observed in the SEM images.

     

Two-Photon Absorption Enhancement by the Inclusion of a Tropone Ring in Distorted Nanographene Ribbons

A new family of distorted ribbon-shaped nanographenes was designed, synthesized, and their optical and electrochemical properties were evaluated, pointing out an unprecedented correlation between their structural characteristics and the two-photon absorption (TPA) responses and electrochemical band gaps. Three nanographene ribbons have been prepared: a seven-membered-ring-containing nanographene presenting a tropone moiety at the edge, its full-carbon analogue, and a purely hexagonal one. We have found that the TPA cross-sections and the electrochemical band gaps of the seven-membered-ring-containing compounds are higher and lower, respectively, than those of the fully hexagonal polycyclic aromatic hydrocarbon (PAH). Interestingly, the inclusion of additional curvature has a positive effect in terms of non-linear optical properties of those ribbons.     

Tandem Use of Optical Sensing and Machine Learning for the Determination of Absolute Configuration,Enantiomeric and Diastereomeric Ratios,and Concentration of Chiral Samples

We have developed an optical method for accurate concentration, er, and dr analysis of amino alcohols based on a simple mix‐and‐measure workflow that is fully adaptable to multiwell plate technology and microscale analysis. The conversion of the four aminoindanol stereoisomers with salicylaldehyde to the corresponding Schiff base allows analysis of the dr based on a change in the UV maximum at 420 nm that is very different for the homo‐ and heterochiral diastereomers and of the concentration of the sample using a hypsochromic shift of another absorption band around 340 nm that is independent of the analyte stereochemistry. Subsequent in situ formation of Cu^II assemblies in the absence and presence of base enables quantification of the er values for each diastereomeric pair by CD analysis. Applying a linear programming method and a parameter sweep algorithm, we determined the concentration and relative amounts of each of the four stereoisomers in 20 samples of vastly different stereoisomeric compositions with an averaged absolute percent error of 1.7 %.     

Comparative bioavailability of two zolpidem hemitartrate formulations in healthy human Brazilian volunteers using high-performance liquid chromatography coupled to tandem mass spectrometry

To assess the bioequivalence of two zolpidem hemitartrate formulations in 30 healthy volunteers. Plasma samples were obtained over a 24 h period. Plasma concentrations of zolpidem were analyzed by liquid chromatography coupled to tandem mass spectrometry with positive ion electrospray ionization using multiple reaction monitoring. Values of peak concentration (C_max), area under curve (AUC), half-life, elimination constant, volume of distribution and clearance showed statistically significant differences when comparing women (604.34 ng h/ml, 127.36 ng/ml, 4.4 h, 0.18 1/h, 50.56 L and 8.55 L/h, respectively) and men (276.1 ng h/ml, 70.9 ng/ml, 3.3 h, 0.26 1/h, 91.42 L and 24.34 L/h, respectively), receiving the same dose (5 mg), respectively. The geometric means with corresponding 90% confidence interval for Test/Reference percentage ratios were 99.73% (CI 93.69–106.16) for C_max, 97.44% (90% CI = 91.85–103.37%) for area under curve of plasma concentration until the last concentration observed (AUC_last) and 98.30% (90% CI = 92.48–104.49) for the area under curve between the first sample (pre-dosage) and infinity (AUC_0–inf). Since the 90% CI for AUC_last, AUC_0–inf and C_max ratios were within the 80–125% interval proposed by the US Food and Drug Administration, it was concluded that zolpidem hemitartrate formulation (5 mg orodispersible tablet) is bioequivalent to the zolpidem hemitartrate formulation (Patz SL 5 mg sublingual tablet) with regard to both the rate and the extent of absorption. A new formulation of zolpidem 2.5 mg may be useful in women for the same clinical benefits as the 5 mg formulation in men.